In today's edition of Market Checkup, health-care analysts David Williamson and Max Macaluso take a close look at Merck, a Dow component and one of the biggest players in the pharmaceutical industry. They analyze the highlights from Merck's second-quarter results and examine the company's main vulnerabilities.

David Williamson owns shares of Pfizer. Max Macaluso, Ph.D. owns shares of Gilead Sciences. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.